Diabetes is a metabolic disorder that can result from insufficient Insulin supplies or reduced capacity to use insulin in in the body. Blood sugar is too high. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which are responsible for the administration of drugs units stated that there was no clear evidence that treatment of Type 2 diabetes could lead to Pancreatic cancer . Nevertheless, it is premature to say that drugs for type 2 diabetes are associated with Pancreatitis or have no connection between them.
Relationship between diabetic drugs and pancreatic cancer
Millions of people worldwide suffer from diabetes, and type 2 diabetes is the most common type. Incretin is a drug that secretes cells in the small intestine and produces a hormone that promotes insulin secretion after eating or oral glucose. The latest drugs for the treatment of type 2 diabetes. Two other enteroxin-based drugs are: glycin-1 peptide-1 promoter (GLP-1 agonists), dipeptide peptide-4 inhibitors (DPP-4) inhibitors.
Glycin peptide-1 promoter prevents and delay stomach emptying, stimulates insulin secretion, thereby lowering blood glucose. The drugs for glycin-1 promoters are Exenatide and Liraglutide. It is worth noting that Inattae was first approved by the FDA in 2005, a type 2 diabetes treatment drug based on enteroin.
On the other hand, dipeptide peptide-4 inhibitors slow the absorption of glucose in the stomach, inhibit hormonal secretion that raises blood glucose, and promote insulin secretion. In 2006, the US Food and Drug Administration approved Sitagliptin as a drug that is a dipeptide peptide-4 inhibitor.
Current article: Can Diabetes Medication Cause Pancreatic Cancer?
A few years later, the FDA received reports of pancreatitis and pancreatic cancer patients taking glycin-1 peptide-1 promoter and dipeptide-4 inhibitors. Although there is no evidence to show or prove, the risk of taking these drugs to the pancreas has been significantly increased in patients with type 2 diabetes. Some scientists point out that because these drugs cause weight loss in humans; glycin-1 promoters are generally prescribed for overweight patients, who are already suffering from a higher risk of pancreatic disease.
Later, the FDA, the European Drug Administration, the two government units responsible for drugs, conducted approximately 250 toxicology for nearly 18,000 healthy animals toxicology study. It was not found that intestinal insulin-based drugs increased the risk of pancrea-related diseases in animals. In addition, the two authorities also reviewed hundreds of human drug trials and showed that there was no correlation between insulin-based drugs and people suffering from pancrea-related diseases.
Whether patients with diabetes should continue to take these medications
The American Diabetes Association recommends that patients should not stop taking drugs on their own without adequate discussion with their physicians. Before starting to take these medications, patients should be fully aware of the risks and benefits of taking them in order to make the best choice for themselves.
If patients stop taking drugs without first consulting and discussing with their physician, their body may have a higher risk of complications such as heart disease, stroke, kidney damage, and even blindness.